On October 26, 2024, Biogen Inc. presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in patients with IgA nephropathy (IgAN). The data, shared at Kidney Week 2024, the American Society of Nephrology’s annual meeting, showed substantial reductions in proteinuria and stabilization of kidney function.
Patients who received a nine-dose regimen of felzartamab over a six-month treatment period experienced a mean reduction of approximately 50% in the urinary protein:creatinine ratio (UPCR) through month 24, which was more than 18 months after the last dose. Kidney function, as measured by the estimated glomerular filtration rate (eGFR), also stabilized. These results suggest that felzartamab may offer durable benefits and potentially allow for treatment cycles rather than continuous dosing.
Further analysis indicated that felzartamab selectively and durably reduced IgA antibody levels, while IgG and IgM levels recovered to baseline three months off-treatment, potentially maintaining essential immune functions. The overall safety profile was consistent with prior studies. Biogen plans to initiate Phase 3 trials for felzartamab in IgAN in 2025, highlighting its potential as a meaningful treatment option for this leading cause of chronic kidney disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.